• Active, not recruiting

NCT02663518: Phase 1: A Trial of TTI-621 for Patients With Hematologic Malignancies and Solid tumors

Updated: Jun 27

NCT02663518: Phase 1: A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors


tti-622 trillium

NCT02663518: Phase 1: A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors


Multicenter, open-label, phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.


Sponsor

Trillium Therapeutics Inc.

 

ClinicalTrials.gov Identifier: NCT02663518

Official Title: A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

First Posted : January 26, 2016

Click here to see details on ClinicalTrials.gov

 

Drug: TTI-621

Drug: TTI-621 plus Rituximab

Drug: TTI-621 plus Nivolumab

 

TTI 621

Ontorpacept (Code C125718)

Ontorpacept

ONTORPACEPT

SIRPa-Fc Fusion Protein TTI-621

SIRPaFc

TTI 621

TTI-621

 

Locations:

United States, California

United States, Colorado

United States, Florida

United States, Minnesota

United States, New Jersey

United States, New York

United States, Ohio

United States, Oregon

United States, Pennsylvania

United States, Tennessee

United States, Texas

United States, Washington

Canada, British Columbia

Canada, Ontario

 

Pfizer Completes Acquisition of Trillium Therapeutics

Learn more






Posts Archive